Phase II Study of RAD001 in Advanced Cholangiocarcinoma.

Trial Profile

Phase II Study of RAD001 in Advanced Cholangiocarcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Everolimus (Primary)
  • Indications Cholangiocarcinoma; Gallbladder cancer
  • Focus Therapeutic Use
  • Acronyms RADiChol
  • Most Recent Events

    • 12 Mar 2018 Status changed to completed, according to results published in the British Journal of Cancer.
    • 12 Mar 2018 Primary endpoint (Disease control rate (DCR) at 12 weeks) has not been met, according to results published in the British Journal of Cancer.
    • 12 Mar 2018 Results published in the British Journal of Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top